Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. May 24, 2026; 17(5): 120140
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.120140
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.120140
Prognostic value of lung immune prognostic index in stage I non-small cell lung cancer treated with stereotactic body radiotherapy: A two-center study
Wei-Hua Gao, Qing-Yao Zhu, Qiang Jiang, Li-Xia Lian, Department of Radiation Oncology, Henan Provincial People’s Hospital, Zhengzhou 450003, Henan Province, China
Hui Luo, Department of Radiation Oncology, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China
Author contributions: Gao WH and Zhu QY participated in the conception and design of the study; Gao WH, Zhu QY, Luo H, Jiang Q, and Lian LX were involved in the acquisition, analysis, or interpretation of data; Gao WH and Zhu QY wrote the manuscript; Gao WH, Zhu QY, and Luo H accessed and verified the study data; and all authors critically reviewed and approved the final manuscript to be published.
AI contribution statement: Deepseek has been used for language polishing of the manuscript (the results and discussion section). There was no Artificial Intelligence tool that participate in design of the study or interpretation of the results. All the images in the manuscript was generated by the authors themself.
Institutional review board statement: The present study was approved by the Research Ethics Committee of the Zhengzhou University People’s Hospital and Cancer Hospital.
Informed consent statement: Informed consent statement was finished prior to anticancer therapy.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Not applicable.
Corresponding author: Qing-Yao Zhu, Research Dean, Department of Radiation Oncology, Henan Provincial People’s Hospital, Weiwu Road, Zhengzhou 450003, Henan Province, China. lindayue7768@sina.com
Received: February 24, 2026
Revised: March 15, 2026
Accepted: April 10, 2026
Published online: May 24, 2026
Processing time: 93 Days and 20.5 Hours
Revised: March 15, 2026
Accepted: April 10, 2026
Published online: May 24, 2026
Processing time: 93 Days and 20.5 Hours
Core Tip
Core Tip: The pretreatment lung immune prognostic index (LIPI) serves as a useful, independent prognostic marker for patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy. Based on routine blood counts and lactate dehydrogenase levels, LIPI effectively stratifies patients into distinct risk groups, with those classified as “Poor LIPI” experiencing significantly shorter median overall survival compared to those with “Good LIPI”. This readily available tool can supplement traditional evaluations to identify high-risk individuals who may benefit from closer monitoring.